ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)

Manufacturer
Fenwal, Inc. | Fenwal International, Inc.
Effective date
2019-04-19
Label type
Human Prescription Drug Label
Version
5
Source
full-release
Hydrated at
2026-05-31 20:28:33

Label at a glance#

ProductADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)
Active ingredientTrisodium Citrate Dihydrate, Dextrose Monohydrate, Anhydrous Citric Acid, Sodium Phosphate, Monobasic, Monohydrate, Sodium Chloride, Mannitol, Adenine
Label structure2 sections

Label contents#

Full prescribing information#

BLOOD-PACK™ Unit with an Integral SEPACELL™ FLEX-EXCEL™ Leukocyte Reduction Filter Using CPD/ADSOL™ Red Cell Preservation Solution for Whole Blood Collection and Filtration of Red Blood Cells

SPL UNCLASSIFIED SECTION

Rx only
Contains Sample Diversion System for the collection of whole blood samples for laboratory testing. Also includes the DONORCARE™ Needle Guard.
Integral filter unit intended for leukocyte reduction of AS-1 red blood cells:

•At ambient temperature up to 8 hours after blood collection.
•At refrigerated temperature up to 3 days after blood collection if AS-1 red blood cells are prepared within 3 days after whole blood collection.
The leukocyte reduced red blood cells may then be stored for the maximum allowable dating period.

Instructions for Use
Collection Procedure:
Use aseptic technique.
Notes:
• If sample diversion system is not used, donor samples may be collected using an alternate method following standard procedures.
• Nominal tubing dimensions of product are 0.118" inner diameter x 0.025" wall thickness.
Precautions:
• Upon removal of BLOOD-PACK™ unit from the clear plastic overwrap, visually inspect the unit.
• Do not use the product if the in-line cannula is broken and/or anticoagulant is present in the sample pouch or in the tubing from the in-line cannula to the sample pouch and donor needle (see Figure 1). Note that condensation in the empty tubing of the BLOOD-PACK unit is expected as a result of the sterilization process.
• Do not use unless the solutions are clear.
1. Identify BLOOD-PACK unit using appropriate donor identification system.
2. Donor scale
• Adjust donor scale to desired collection weight.
• Position primary container on the donor scale as far as possible below donor arm.
3. Clamp donor tubing between the needle and Y-junction with hemostat. (This step can be performed prior to step 1 or 2.)
4. Visually inspect the tubing from the in-line cannula to the sample pouch and donor needle, as well as the sample pouch to reconfirm that there is no anticoagulant present.
Note: Ensure that the sample pouch remains below the donor's arm.
5. Follow blood center procedures, apply pressure to donor's arm and disinfect site of venipuncture.
6. Remove needle cover per instructions below:
• Holding the hub and cover near the tamper-evident seal, twist cover 1/4 turn to break seal.
• Remove needle cover, being careful not to drag the cover across the needle point.
7. Following blood center procedures, perform venipuncture, appropriately secure donor needle and/or tubing and release hemostat.
8. When good blood flow is established, slide the DONORCARE™ needle guard over the needle hub into the engaged position. Leave the front third of the needle hub exposed for access. Stabilize the front of the needle guard to arm with tape. (see Figure 2)
Note: In difficult collection conditions (e.g., slow blood flow), leave the needle guard disengaged behind the hub during collection. Engage the needle guard at the end of blood collection. Appropriately secure needle and/or tubing.
9. Allow the sample pouch to fill with blood according to center procedure. Monitor blood flow into sample pouch.
Notes:
• The sample pouch contains an average fill volume of approximately 53 mL with a maximum fill volume of approximately 60 mL when filled to capacity.
• If less blood sample volume is required, the flow to the sample pouch may be stopped prior to completely filling the pouch. For example, in order to target a fill volume of approximately 40 mL, fill to the level indicated by the arrows in Figure 1. Ensure the pouch is hanging vertically.
• The tube leading from the Y-junction to the sample pouch contains an additional volume of approximately 2 mL .
Precautions:
• Do not elevate or squeeze the sample pouch as this could cause blood to backflow from the sample pouch into the collection system.
• Once the sample pouch is filled to desired volume, complete steps 10 - 18 within approximately 4 minutes to avoid possible clot formation in the tubing and/or sample pouch.
10. Close the blue clamp on tubing between the Y-junction and the sample pouch.
11. Break the in-line cannula below the Y-junction in the donor tubing to the primary container allowing blood collection to proceed. To completely break the in-line cannula, grasp with both hands. Snap it at a 90° angle in one direction, and then bend it at a 90° angle in the opposite direction. Ensure the in-line cannula is completely broken and that the blood flows freely to the primary container.
Precaution: Failure to break the in-line cannula completely may result in restricted blood flow.
12. Following blood center procedures, mix blood and anticoagulant in the primary container immediately and at several intervals during collection.
13. Following blood center procedures, hermetically seal the tubing between the sampling site and the Y-junction to maintain sterility of the blood collection system prior to removing blood samples.
Warning:
• Do not proceed with the remaining steps until the tubing leading to the sample pouch is hermetically sealed between the sampling site and the Y-junction. To maintain the whole blood collection container as a closed system, the tubing between the sample pouch and Y-junction must be hermetically sealed prior to inserting the access device into the sampling site. Failure to do so may lead to contamination of the whole blood collection.
14. Insert the access device by pushing firmly into the sampling site until the membrane seal is penetrated.
Note: If the access device is assembled such that the outer barrel is screwed onto the Luer, make sure to rotate clockwise upon insertion to avoid barrel detaching from Luer.
15. Open the cap on the access device (if applicable). Hold access device so that the sample pouch hangs down.
16. Directly align the vacuum sample tube with the internal needle in the access device. Insert vacuum sample tube into device.
17. Allow vacuum sample tube to fill with blood then remove from the access device.
18. Repeat steps 16 and 17 until the desired number of vacuum sample tubes have been filled.
Notes:
• If the access device needs to be replaced, use a hemostat to clamp the tubing between the sampling site and the sample pouch. Then, grasp base of sampling site with one hand and pull the access device out with the other hand. Firmly insert the new access device. Remove hemostat and continue sampling.
• If the access device is assembled such that the outer barrel is screwed onto the Luer, make sure to rotate clockwise upon removal to avoid barrel detaching from Luer.
• The access device can only be replaced one time.
Precaution: When replacing access device, be careful to avoid contact with any blood droplets on the
Luer or sampling site. Discard used access device appropriately.
19. Collect the appropriate volume based on BLOOD-PACK unit used.
Note: The volume of anticoagulant is sufficient for the blood collection indicated on BLOOD-PACK unit ± 10%.
Precaution: Once the desired blood volume is collected, complete steps 20-24 within approximately 4 minutes to avoid possible clot formation in the tubing.
20. Release pressure on the donor’s arm. If appropriate, apply hemostat to donor tubing between the needle and the Y-junction.
21. Hermetically seal donor tubing between the in-line cannula and the primary container.
22. Withdrawal of Needle (see Figure 3)
Precaution: The needle guard must be held stationary while the needle is withdrawn into it.
a) Place folded sterile gauze over puncture site and hold in place with finger tip without exerting pressure.
b) Hold sides of needle guard near the front, between the index finger and thumb. Pull the tubing smoothly until the needle is locked into the needle guard.
c) Confirm the needle lock by:
• Listen for the 2nd “click” as the needle is drawn into the needle guard.
• Ensure the tubing cannot be pulled through the needle guard.
23. Remove and discard the sample diversion system and needle guard into an appropriate biohazardous waste container following established procedures.
Note: Step 24 may be performed prior to step 23 if desired.
24. If the donor tubing is not hermetically sealed directly above the primary container, then strip the blood from the remaining donor tubing into the primary container. Mix and allow tubing to refill; repeat once.
Component Preparation:
Notes:
• If a platelet concentrate is to be prepared, it should be separated within 8 hours after blood collection.
• Fresh frozen plasma should be separated from the red blood cells and placed in the freezer at -18°C or colder within 8 hours after blood collection.
• ADSOL™ red cell preservation solution should be added to the red blood cells immediately after the removal of plasma. Preparation of AS-1 red blood cells may vary depending on processing option selected:
a) Within 8 hours of blood collection if whole blood is held at ambient temperature.
b) Within 3 days of blood collection if whole blood is refrigerated.
25. At the appropriate time, prepare the BLOOD-PACK unit with Integral Filter for centrifugation.
26. Thoroughly mix the primary container end over end.
27. Load the BLOOD-PACK Unit into a centrifuge cup per the instructions on page 3 or 4.
Page 3 describes Option A, the coil tubing method of cup loading.
Page 4 describes Option B, the drop tubing method of cup loading.
Notes:
• This guide is one method for centrifuge cup loading and applies to all Flex-Excel configurations. The specific stacking order and methods may vary depending on the workstation setup, centrifuge equipment, and Standard Operating Procedures.
• It is important to pack the filter properly in the centrifugation cup to avoid damage to the filter during centrifugation.
• Check valve must be placed in a horizontal position (Figure 4a, page 2). Avoid the clear (red tip) side from pointing downward (Figure 4b, page 2). See step 3 on page 3 or 4.
• Do not place the filter, breakaway cannula or check valve in the lower half of the centrifuge cup.
See step 5 on page 3 or 4.
28. After loading the BLOOD-PACK Unit into the centrifuge cup, perform centrifugation according to center procedures.
29. Following centrifugation, remove containers from the centrifugation cup taking care not to disturb the red blood cell / plasma interface.
30. Place primary container in a plasma extractor and apply pressure. If applicable, clamp off tubing below Y-Junction leading to secondary TRANSFER-PACK™ container not to be filled with plasma. Open the cannula on the top of the primary container to transfer plasma into the empty TRANSFER-PACK container.
31. When the desired amount of plasma has been removed, clamp the tubing between the plasma container and the Y-connector closest to the plasma container and release pressure on the primary container.
32. Suspend the ADSOL red cell preservation solution container, open the cannula on the ADSOL solution container and drain the contents into the primary container of the CPD red blood cells. Clamp the ADSOL red cell preservation solution tubing.
33. Hermetically seal the tubing between the Y-connectors or above the plasma TRANSFER-PACK container.
Be careful to avoid fluid splatter.
34. Mix the ADSOL red cell preservation solution and red cells thoroughly.
Note: If the ADSOL red cell preservation solution is not added to the red cells, ensure appropriate labeling of the red cell container. The pre-filter container does not include tubing with segment numbers.
A CPD red cell without ADSOL red cell preservation solution may be stored between 1 and 6ºC up to 21 days after collection. The attached SEPACELL™ FLEX-EXCEL™ filter should not be used to leukoreduce a CPD red cell without ADSOL red cell preservation solution.
Filtration Procedure:
Precaution
: Red blood cell products collected from certain donors may have extended filtration times and the potential for ineffective filtration and leukoreduction.
35. Mix unfiltered AS-1 red blood cells thoroughly. Invert the unfiltered AS-1 red blood cells and hang the filter set such that the filter remains vertical. To achieve maximum flow rate, allow the set to hang to full length.
Note: The storage container must remain below the level of the filter during filtration.
36. Inspect all tubing to ensure it hangs freely without kinks. If desired, a temporary clamp may be placed on the vent line, but must be removed prior to expelling air through the vent line.
37. Break the in-line cannula above the filter to start filtration.
Note: Manual or mechanical pressure should not be used to increase the flow rate through the filter.
Note: Tubing below the filter should not be stripped at any time during the filtration process.
Note:
If filtration of red cells is initiated at ambient temperature, the filtration process can be completed at either ambient or refrigerated temperature prior to storing the red cells between 1 and 6°C.
However, for optimal filtration time, it is recommended to complete the filtration at ambient temperature.
38. As the filtered red cell storage container is filling, or when flow stops, clamp or pinch the tubing below the filter to occlude flow.
Note: While the check valve is designed to prevent blood flow from entering the vent line below the valve, blood may flow down and fill the valve.
39. Squeeze the filtered red cell storage container to expel air from the filtered red cell container through the vent line. Continue squeezing the filtered red cell container until the vent line segments and check valve are filled with blood as desired.
40. Remove the clamp or release the tubing below the filter to resume red cell flow through the filter. If desired, the temporary clamp may be replaced on the vent line immediately after removing the clamp below the filter. When filtration is complete, air can be observed in the inlet side of the filter.
Note: While the check valve is designed to prevent blood flow from entering the vent line below the valve, it is normal for air to pass through the valve and enter the vent line tubing. To avoid air from entering the vent line below the valve, the vent line may be clamped during this step, or blood may be expressed beyond the check valve during the air expel operation.
41. Hermetically seal and detach the tubing below the filter. Also, hermetically seal and detach the vent line between the one way valve and the top donor segment number.
42. Make segments from the vent line tubing and leave segments attached to the filtered red cell storage container. (QC samples may be prepared by thoroughly mixing the filtered red cells and stripping this tubing prior to sealing the segments.)
43. Store the AS-1 red blood cells, leukocytes reduced between 1 and 6°C.
44. Infuse the red cells within 42 days of collection.
Warning: Failure to achieve closed system processing conditions negates the extended storage claim and the red blood cell product must be transfused within 24 hours.
image01image01


image02
image02

Store at Controlled Room Temperature.
USP Definition of “Controlled Room Temperature” United States Pharmacopeia, General Notices. United States Pharmacopeial Convention, Inc.
12601 Twinbrook Parkway, Rockville, MD



afig1
afig1

afig2
afig2




bfig1
bfig1


bfig2
bfig2


mf1
mf1

Fenwal, Inc.
Lake Zurich, IL 60047 USA
Made in USA
1-800-933-6925



mf2
mf2

Manufacturer
FENWAL, BLOOD-PACK, TRANSFER-PACK, ADSOL and FLEX-EXCEL are trademarks of Fenwal, Inc.
SEPACELL is a trademark of Asahi Kasei Medical Co., Ltd.
DONORCARE is a trademark of ITL Corporation.
© 2018 Fenwal, Inc. All rights reserved.


07-19-13-106 REV: A

PACKAGE/LABEL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Code 4R1590P

9 Units

Fenwal™

Anticoagulant Citrate Phosphate Dextrose Solution, USP (CPD) BLOOD-PACK® Unit; TRANSFER-PACK® Container with ADSOL® Red Cell Preservation Solution; Integral SEPACELL® FLEX-EXCEL® Red Cell Leukocyte Reduction Filter

Quadruple For Collection and Processing of 500 mL Blood

Sample Diversion System, DONORCARE® Needle Guard, 16 ga. Ultra Thin Wall Needle

Rx only

Each unit consists of a PL 146 Plastic primary container with 70 mL of CPD solution containing 1.84 g Sodium Citrate (dihydrate) USP, 1.78 g Dextrose (monohydrate) USP, 209 mg Citric Acid (anhydrous) USP, 155 mg Monobasic Sodium Phosphate (monohydrate) USP, pH may have been adjusted with sodium hydroxide; one 400 mL PL 2209 Plastic Satellite Container with 110 mL of Adsol Red Cell Preservation Solution containing 2.42 g Dextrose (monohydrate) USP, 990 mg Sodium Chloride USP, 825 mg Mannitol USP, 30 mg Adenine USP; one empty 400 mL PL 2209 Plastic TRANSFER PACK Containers; one integral SEPACELL FLEX-EXCEL Red Cell Leukocyte Reduction Filter and one empty 450 mL PL 2209 Plastic TRANSFER PACK Container for the storage of AS-1 Red Blood Cells, Leukocytes Reduced.

Sterile, non-pyrogenic fluid path.
See instructions for use.

Store at Controlled Room Temperature (refer to direction insert).

  • Open pouch by tearing across at notch.
  • Unused units in open foil pouch may be kept up to 60 days by folding and securing open end of foil pouch to prevent possible loss of moisture, provided:

l) Units are not removed from foil pouch, or
ll) Unused units removed from foil pouch are returned to the foil pouch within 12 hours. Units may be removed from the pouch and returned only once.


  • Direct handling of product surfaces prior to extended storage in the foil pouch, may result in mold growth. 
  • Units removed from the foil pouch (that are not returned to the pouch within 12 hours)must be used within 4 days (96 hours). Units out of the foil pouch for longer than 4 days must be discarded.

FENWAL, BLOOD-PACK, ADSOL, TRANSFER PACK and FLEX-EXCEL are trademarks of Fenwal, Inc.
SEPACELL is a trademark of Asahi Kasei Medical Co., Ltd. 
DONORCARE is a trademark of Noble House Group Pty. Ltd..
PL 146 and PL 2209 are trademarks of Baxter International Inc.
 

mfg3mfg3
Fenwal, Inc.

Lake Zurich, IL 60047 USA

Made in USA

07-28-12-663 REV: A

primlblprimlbl

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
ANHYDROUS CITRIC ACID Pharmacologic Class Indexing3Indexing - Pharmacologic Class20180813
MANNITOL Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813
SODIUM CATION Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
95250459-30e4-45c1-b08a-993044f49109Product name220250805
efd58dcf-540a-4531-8766-e713129ca6f2Product name120250307
4b7700e3-6e0e-45e5-9d22-6f754d61386eProduct name220250304
726062af-1135-4707-a1d7-57256991bbf9Product name220250226
a21a21e5-f36d-4c1f-8918-def921b8f7e3Product name320250124
fb7ab793-2c12-4079-b100-a64f73bef25aProduct name420240712
b0cbf770-6cc3-4aa4-9158-755110c2b9f7Product name220230717
cb89b86a-369e-4204-8910-ae797c503af3Product name120230706
dc7c5daa-021f-40dd-b00d-63982cb2067aProduct name120230426
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
9badc7be-250a-44ab-aa36-926af3f02679Product name120210527
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name520200925
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
d4880ace-a516-8c47-8dfd-73a4ba5887d7Product name220180830
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
26acd337-b838-40ac-bcbc-05c3b81c8712Product name120170323
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name220160823
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
19c71a3d-ed9c-166b-a7e5-38c250c35631Product name120140508
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
597b1cfd-7b31-5048-62be-ca5cd740da2fProduct name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0942-6493-04ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)1 in 1 KITKIT15

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0942-6493ADSOL RED CELL PRESERVATION SOLUTION SYSTEM IN PLASTIC CONTAINER (PL 146 PLASTIC) (ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE (CPD) SOLUTION AND ADSOL PRESERVATION SOLUTION) KIT [FENWAL, INC.]5Current NDC, Legacy NDC, 1 package rows20190503_ba4eae32-7f0d-4bdd-937f-3a85d6fbf0ba.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
AdenineACTIVE INGREDIENTJAC85A21614
Anhydrous Citric AcidACTIVE INGREDIENTXF417D3PSL4
Dextrose MonohydrateACTIVE INGREDIENTLX22YL083G4
MannitolACTIVE INGREDIENT3OWL53L36A4
Sodium ChlorideACTIVE INGREDIENT451W47IQ8X4
Sodium Phosphate, Monobasic, MonohydrateACTIVE INGREDIENT593YOG76RN4
Trisodium Citrate DihydrateACTIVE INGREDIENTB22547B95K4
AdenineACTIVE MOIETYJAC85A21614
Anhydrous Citric AcidACTIVE MOIETYXF417D3PSL4
ANHYDROUS DEXTROSEACTIVE MOIETY5SL0G7R0OK4
MannitolACTIVE MOIETY3OWL53L36A4
PHOSPHATE IONACTIVE MOIETYNK08V8K8HR4
SODIUM CATIONACTIVE MOIETYLYR4M0NH374
Sodium HydroxideINACTIVE INGREDIENT55X04QC32I4

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 17 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0942-64930942-6493-04

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML · Source PDF

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 6 · 348 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IGEL / TOPICAL70 mgExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IPASTE / DENTAL0.6 %w/wExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IJELLY / TOPICALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / DENTALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR0.35 %w/vExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBMUCOSALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBARACHNOIDADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / SUBMUCOSALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISUSPENSION/ DROPS / OPHTHALMICADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION/ DROPS / TOPICALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRA-ARTICULARADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISPRAY, METERED / NASALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / PERIDURALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IPOWDER, FOR SUSPENSION / ORAL9 mgExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ITABLET / ORAL10 mgExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRAPERITONEALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRAVASCULARADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / URETERALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / PERIDURALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IFILM / BUCCAL0.09 mgExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRALESIONALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / ORAL9120 mgExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRALESIONALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / ENDOTRACHEALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR7.01 mgExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IPOWDER, FOR SOLUTION / ORALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / INTRAMUSCULARADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, EMULSION / INTRAVENOUSADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IOINTMENT / TOPICALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRACAUDALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / DENTALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / PERIODONTALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / IRRIGATIONADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRA-ARTICULARADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRAVENOUS456 mgExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IAEROSOL, METERED / RESPIRATORY (INHALATION)ADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / OPHTHALMIC0.05 %w/vExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ICREAM, AUGMENTED / TOPICAL6 mgExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRATUMORADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISUSPENSION / ORAL400 mgExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SUSPENSION / INTRAVENOUSADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBMUCOSALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IGEL / OPHTHALMIC6 mgExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISPRAY, METERED / NASALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / SOFT TISSUEADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IPOWDER / INTRAVENOUSADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ILIQUID / INTRAMUSCULARADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRAVENOUSADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / EPIDURALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / INTRAOCULARADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / SUBCUTANEOUS31.45 mgExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRALESIONALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / ENDOTRACHEALADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IGEL / OPHTHALMIC6 mgExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISYRUP / ORAL71 mg/5mlExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INFILTRATIONADJ PHExact identifier — unii candidate
348 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / INTRAVENOUS2.78 %w/vExact identifier — unii candidate
348 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE (CPD) SOLUTION AND ADSOL PRESERVATION SOLUTIONFenwal, Inc.ba4eae32-7f0d-4bdd-937f-3a85d6fbf0ba2019-04-19Exact identifier
ndc (package): 0942-6493-04
ndc (product): 0942-6493
ndc11 (package): 00942649304
spl id: 7f7a7602-0dde-4b35-af52-3147eb773397
spl set id: ba4eae32-7f0d-4bdd-937f-3a85d6fbf0ba

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.